XML 28 R7.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
shares in Millions, $ in Millions
Total
Total Edwards Lifesciences Corporation Stockholders' Equity
Common Stock
Treasury Stock
Additional Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive Loss
Noncontrolling Interest
Common stock, beginning balance (in shares) at Dec. 31, 2021     642.0          
Beginning balance at Dec. 31, 2021 $ 5,835.9   $ 642.0 $ (2,416.9) $ 1,700.4 $ 6,068.1 $ (157.7)  
Treasury stock, beginning balance (in shares) at Dec. 31, 2021       17.9        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 373.6         373.6    
Other comprehensive income (loss), net of tax (28.9)           (28.9)  
Common stock issued under stock/equity plans (in shares)     0.9          
Common stock issued under stock/equity plans 37.5   $ 0.9   36.6      
Stock-based compensation expense 32.4       32.4      
Purchases of treasury stock (in shares)       3.6        
Purchases of treasury stock (405.6)     $ (405.6)        
Common stock, ending balance (in shares) at Mar. 31, 2022     642.9          
Ending balance at Mar. 31, 2022 5,844.9   $ 642.9 $ (2,822.5) 1,769.4 6,441.7 (186.6)  
Treasury stock, ending balance (in shares) at Mar. 31, 2022       21.5        
Common stock, beginning balance (in shares) at Dec. 31, 2021     642.0          
Beginning balance at Dec. 31, 2021 5,835.9   $ 642.0 $ (2,416.9) 1,700.4 6,068.1 (157.7)  
Treasury stock, beginning balance (in shares) at Dec. 31, 2021       17.9        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 1,123.5              
Common stock, ending balance (in shares) at Sep. 30, 2022     645.7          
Ending balance at Sep. 30, 2022 6,217.8   $ 645.7 $ (3,278.0) 1,914.5 7,191.6 (256.0)  
Treasury stock, ending balance (in shares) at Sep. 30, 2022       26.3        
Common stock, beginning balance (in shares) at Mar. 31, 2022     642.9          
Beginning balance at Mar. 31, 2022 5,844.9   $ 642.9 $ (2,822.5) 1,769.4 6,441.7 (186.6)  
Treasury stock, beginning balance (in shares) at Mar. 31, 2022       21.5        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 406.4         406.4    
Other comprehensive income (loss), net of tax (37.8)           (37.8)  
Common stock issued under stock/equity plans (in shares)     2.1          
Common stock issued under stock/equity plans 49.0   $ 2.1   46.9      
Stock-based compensation expense 36.2       36.2      
Purchases of treasury stock (in shares)       3.7        
Purchases of treasury stock (355.1)     $ (355.1)        
Common stock, ending balance (in shares) at Jun. 30, 2022     645.0          
Ending balance at Jun. 30, 2022 5,943.6   $ 645.0 $ (3,177.6) 1,852.5 6,848.1 (224.4)  
Treasury stock, ending balance (in shares) at Jun. 30, 2022       25.2        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 343.5         343.5    
Other comprehensive income (loss), net of tax (31.6)           (31.6)  
Common stock issued under stock/equity plans (in shares)     0.7          
Common stock issued under stock/equity plans 32.4   $ 0.7   31.7      
Stock-based compensation expense 30.3       30.3      
Purchases of treasury stock (in shares)       1.1        
Purchases of treasury stock (100.4)     $ (100.4)        
Common stock, ending balance (in shares) at Sep. 30, 2022     645.7          
Ending balance at Sep. 30, 2022 $ 6,217.8   $ 645.7 $ (3,278.0) 1,914.5 7,191.6 (256.0)  
Treasury stock, ending balance (in shares) at Sep. 30, 2022       26.3        
Common stock, beginning balance (in shares) at Dec. 31, 2022 608.3   646.3          
Beginning balance at Dec. 31, 2022 $ 5,806.7 $ 5,806.7 $ 646.3 $ (4,144.0) 1,969.3 7,590.0 (254.9) $ 0.0
Treasury stock, beginning balance (in shares) at Dec. 31, 2022 38.0     38.0        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income $ 340.5 340.5       340.5    
Other comprehensive income (loss), net of tax (0.5) (0.5)         (0.5)  
Common stock issued under stock/equity plans (in shares)     0.8          
Common stock issued under stock/equity plans 41.9 41.9 $ 0.8   41.1      
Stock-based compensation expense 38.9 38.9     38.9      
Purchases of treasury stock (in shares)       3.1        
Purchases of treasury stock (249.5) (249.5)   $ (249.5)        
Changes to noncontrolling interest 84.0             84.0
Common stock, ending balance (in shares) at Mar. 31, 2023     647.1          
Ending balance at Mar. 31, 2023 $ 6,062.0 5,978.0 $ 647.1 $ (4,393.5) 2,049.3 7,930.5 (255.4) 84.0
Treasury stock, ending balance (in shares) at Mar. 31, 2023       41.1        
Common stock, beginning balance (in shares) at Dec. 31, 2022 608.3   646.3          
Beginning balance at Dec. 31, 2022 $ 5,806.7 5,806.7 $ 646.3 $ (4,144.0) 1,969.3 7,590.0 (254.9) 0.0
Treasury stock, beginning balance (in shares) at Dec. 31, 2022 38.0     38.0        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income $ 1,029.7              
Common stock, ending balance (in shares) at Sep. 30, 2023 606.5   649.9          
Ending balance at Sep. 30, 2023 $ 6,727.1 6,657.5 $ 649.9 $ (4,576.1) 2,211.3 8,622.5 (250.1) 69.6
Treasury stock, ending balance (in shares) at Sep. 30, 2023 43.4     43.4        
Common stock, beginning balance (in shares) at Mar. 31, 2023     647.1          
Beginning balance at Mar. 31, 2023 $ 6,062.0 5,978.0 $ 647.1 $ (4,393.5) 2,049.3 7,930.5 (255.4) 84.0
Treasury stock, beginning balance (in shares) at Mar. 31, 2023       41.1        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 305.5 307.1       307.1   (1.6)
Other comprehensive income (loss), net of tax (0.1) (0.1)         (0.1)  
Common stock issued under stock/equity plans (in shares)     2.0          
Common stock issued under stock/equity plans 60.8 60.8 $ 2.0   58.8      
Stock-based compensation expense 37.4 37.4     37.4      
Purchases of treasury stock (in shares)       0.1        
Purchases of treasury stock (7.5) (7.5)   $ (7.5)        
Changes to noncontrolling interest (11.6)             (11.6)
Common stock, ending balance (in shares) at Jun. 30, 2023     649.1          
Ending balance at Jun. 30, 2023 6,446.5 6,375.7 $ 649.1 $ (4,401.0) 2,145.5 8,237.6 (255.5) 70.8
Treasury stock, ending balance (in shares) at Jun. 30, 2023       41.2        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 383.7 384.9       384.9   (1.2)
Other comprehensive income (loss), net of tax 5.4 5.4         5.4  
Common stock issued under stock/equity plans (in shares)     0.8          
Common stock issued under stock/equity plans 34.0 34.0 $ 0.8   33.2      
Stock-based compensation expense 32.6 32.6     32.6      
Purchases of treasury stock (in shares)       2.2        
Purchases of treasury stock $ (175.1) (175.1)   $ (175.1)        
Common stock, ending balance (in shares) at Sep. 30, 2023 606.5   649.9          
Ending balance at Sep. 30, 2023 $ 6,727.1 $ 6,657.5 $ 649.9 $ (4,576.1) $ 2,211.3 $ 8,622.5 $ (250.1) $ 69.6
Treasury stock, ending balance (in shares) at Sep. 30, 2023 43.4     43.4